Gapping up In reaction to strong earnings/guidance: AEGR +8.4%, LULU +7.5%, EXPR +6.1%, BLFS +4.8%, BURL +4.4%, PRCP +4%, HOLX +3.3%, AFFX +3%, NLS +2.3%, HCA +1.9%, KKD +1.4%, AMDA +0.5%
M&A news: FMI +116.3% (enters a broad, strategic collaboration with Roche (RHHBY) in the field of molecular information in oncology), TKMR +48.1% (Tekmira Pharma and and OnCore Biopharma Announce merger agreement to create global Hepatitis B virus company), NPSP +8.6% (to be acquired by Shire (SHPG) for $46.00 per share), QGEN +1.2% (acquires Enzymatics Enzyme Solutions Unit)
Select Biotech related names showing strength: RMTI +4.4%, KITE +2.3%, ACHN +1.6%, ARNA +1.3%
Other news: CPXX +20.3% ( announces the publication of Phase 2 data evaluating CPX-351 in adult patients with first-relapse acute myeloid leukemia), ABGB +15.2% (cont strength following late breaking news on Friday), AGEN +13.8% (favorable commentary on Friday's Mad Money), BMY +6.5% (Phase 3 study of Opdivo compared to docetaxel in patients with second-line squamous cell non-small cell lung cancer was stopped early; met its endpoint), SSH +5.9% (provides update; concluded 2014 with 40 enrollments, 21 activated centers, and 12 additional centers committed to participate), OCLS +4.7% (enters into agreement to sell Ruthigen (RTGN) shares for $5.5 mln in event of Ruthigen merger), RIGL +4.6% (announced various updates to its programs and financial status), SUNE +3.8% (SunEdison and Omnigrid Micropower Company announced that they have signed a framework agreement to develop 5,000 rural projects), FRO +3.6% (still checking), AA +1.7% (ahead of earnings later today), PSTI +1.7% (issues letter to shareholders), CLTX +1.6% (announces FDA allowance of IND for Clinical Development of MRX-6 Cream in Atopic Dermatitis, DBVT +1.3% (announces publication in the Journal of Allergy and Clinical Immunology of data demonstrating that epicutaneous immunotherapy may influence the natural history of allergy), BIIB +1.1% (to expand neuropathic pain portfolio with the acquisition of Convergence Pharmaceuticals)
Analyst comments: BLCM +3.2% (initiated with a Buy at Jefferies, initiated with a Overweight at Piper Jaffray), WIN +3.1% (upgraded to Buy from Neutral at BofA/Merrill), FTR +1.8% (upgraded to Buy from Neutral at BofA/Merrill), PCAR +1.2% (upgraded to Outperform at RBC Capital Mkts), ALK +0.5% (upgraded to Buy from Hold at Evercore ISI)
BFW 01/12 13:38 *PT SAYS SHAREHOLDERS MAY CONSIDER SUSPENDING MEETING
BN 01/12 13:38 *PORTUGAL TELECOM COMMENTS IN REGULATORY FILING
BN 01/12 13:37 *PT SAYS SHAREHOLDERS MAY CONSIDER SUSPENDING MEETING
2015-01-12 13:52:54.112 GMT
By Joao Lima
(Bloomberg) -- Portugal Telecom SGPS says shareholders may
consider it appropriate to suspend today’s shareholder meeting,
according to a regulatory filing.
* During shareholder meeting, the approval of the sale of PT
Portugal by Oi depends on exclusive decision of Portugal
Telecom SGPS shareholders
* An announcement with complementary information will be
disclosed to the market this week following ongoing contacts
with securities regulator CMVM
* NOTE Earlier: PT Workers’ Union Will Request Suspension of
Shareholder Meeting Link
Statement: Link
Link to Company News:{PTC PL <Equity> CN <GO>}
Link to Company News:{ATC NA <Equity> CN <GO>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the reporter on this story:
Joao Lima in Lisbon at +351-21-340-4570 or
jlima1@bloomberg.net
To contact the editor responsible for this story:
Henrique Almeida at +351-21-340-4634 or
halmeida5@bloomberg.net